Literature DB >> 31922265

Primary HPV testing with cytology versus cytology alone in cervical screening-A prospective randomized controlled trial with two rounds of screening in a Chinese population.

Karen K L Chan1, Stephanie S Liu1, Na Wei1, Siew F Ngu1, Mandy M Y Chu1, Ka Y Tse1, Lesley S K Lau1, Annie N Y Cheung2, Hextan Y S Ngan1.   

Abstract

We conducted a prospective randomized controlled trial with two screening rounds to evaluate the effectiveness of combining HPV testing with liquid-based cytology (LBC) as a co-test, compared to LBC only in cervical cancer screening of a Chinese population. First, 15,955 women aged 30-60 were randomized at a 1:1 ratio into an intervention group (Digene Hybrid Capture 2 HPV test with LBC) and a control group (LBC alone). Women in the intervention group would be referred for colposcopy and biopsy immediately if they were found to have high-risk HPV regardless of cytology results. The detection of cervical intraepithelial neoplasia grade 2 or above (CIN2+) lesions was significantly higher in the intervention group compared to the control (0.95% vs. 0.38%, OR 2.50, 95% CI 1.65-3.88). At the subsequent round of screening approximately 36 months later, CIN2+ detection was significantly lower in the intervention group (0.08% vs. 0.35%, OR 0.23, 95% CI 0.08-0.57). Over the two rounds of screening, the total detection of CIN2+ was higher in the intervention group (1.01% vs. 0.66%, OR 1.53, 95% CI 1.09-2.19). There was a fourfold increase (10.6% vs. 2.4%, p < 0.001) in the number of colposcopies performed in the intervention arm. Adding a high-risk HPV test to cytology for primary cervical screening led to earlier detection of clinically significant preinvasive lesions, resulting in a reduced detection of CIN2+ lesions in subsequent rounds and an increased rate of colposcopy.
© 2020 UICC.

Entities:  

Keywords:  CIN; HPV testing; cervical cancer; cervical screening; co-testing

Mesh:

Substances:

Year:  2020        PMID: 31922265     DOI: 10.1002/ijc.32861

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Clinical performance of the Roche Cobas 4800 HPV test for primary cervical cancer screening in a Chinese population.

Authors:  Stephanie S Liu; Karen K L Chan; Tina N Wei; Ka Yu Tse; Siew F Ngu; Mandy M Y Chu; Lesley S K Lau; Annie N Y Cheung; Hextan Y S Ngan
Journal:  PLoS One       Date:  2022-08-05       Impact factor: 3.752

2.  Elevated neutrophil-lymphocyte ratio can be a biomarker for predicting the development of cervical intraepithelial neoplasia.

Authors:  Lina Xu; Jiandong Song
Journal:  Medicine (Baltimore)       Date:  2021-07-16       Impact factor: 1.817

3.  Human Papillomavirus Self-Sampling for Primary Cervical Cancer Screening in Under-Screened Women in Hong Kong during the COVID-19 Pandemic.

Authors:  Siew-Fei Ngu; Lesley S K Lau; Justin Li; Grace C Y Wong; Annie N Y Cheung; Hextan Y S Ngan; Karen K L Chan
Journal:  Int J Environ Res Public Health       Date:  2022-02-24       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.